XTL Biopharmaceuticals Sponsored ADR (XTLB) Price & Analysis

Compare

104 Followers

XTLB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.92 - $3.15

Previous CloseN/A

Volume9.89K

Average Volume (3M)3.90K

Market Cap

$15.92M

Enterprise ValueN/A

Total Cash (Recent Filing)$251.00K

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.12

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding12,543,432

10 Day Avg. Volume4,391

30 Day Avg. Volume3,897

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

---

XTL Biopharmaceuticals Sponsored ADR News

PremiumThe Fly

XTL Biopharmaceuticals appoints Noam Band as CEO

22d ago

XTLB

PremiumCompany Announcements

XTL Biopharmaceuticals Appoints Noam Band as CEO

22d ago

XTLB

PremiumCompany Announcements

XTL Biopharmaceuticals Enters Sublicense Agreement with Biossil

2M ago

XTLB

PremiumCompany Announcements

XTL Biopharmaceuticals Adjusts Board Representation Amid Resignations

3M ago

XTLB

PremiumCompany Announcements

XTL Biopharmaceuticals Expands Portfolio with Social Proxy Acquisition Amidst Regional Challenges

4M ago

XTLB

PremiumCompany Announcements

XTL Biopharmaceuticals Reports Financial Results Amid Regional Unrest

4M ago

XTLB

PremiumCompany Announcements

XTL Biopharmaceuticals Adjusts Shares, Eyes Expansion

5M ago

XTLB

PremiumCompany Announcements

XTL Biopharmaceuticals Resolves Dispute with Social Proxy

6M ago

XTLB

See All XTLB News

---

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

0.07%

Mutual Funds

1.59% Other Institutional Investors

98.34% Public Companies and

Individual Investors

Detailed Ownership Overview >

XTLB FAQ

What was XTL Biopharmaceuticals Ltd. Sponsored ADR’s price range in the past 12 months?

XTL Biopharmaceuticals Ltd. Sponsored ADR lowest stock price was $0.92 and its highest was $3.15 in the past 12 months.

What is XTL Biopharmaceuticals Ltd. Sponsored ADR’s market cap?

XTL Biopharmaceuticals Ltd. Sponsored ADR’s market cap is $15.92M.

When is XTL Biopharmaceuticals Ltd. Sponsored ADR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were XTL Biopharmaceuticals Ltd. Sponsored ADR’s earnings last quarter?

XTL Biopharmaceuticals Ltd. Sponsored ADR released its earnings results on May 31, 2023. The company reported -$0.169 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.169.

Is XTL Biopharmaceuticals Ltd. Sponsored ADR overvalued?

According to Wall Street analysts XTL Biopharmaceuticals Ltd. Sponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does XTL Biopharmaceuticals Ltd. Sponsored ADR pay dividends?

XTL Biopharmaceuticals Ltd. Sponsored ADR does not currently pay dividends.

What is XTL Biopharmaceuticals Ltd. Sponsored ADR’s EPS estimate?

XTL Biopharmaceuticals Ltd. Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does XTL Biopharmaceuticals Ltd. Sponsored ADR have?

XTL Biopharmaceuticals Ltd. Sponsored ADR has 12,543,432 shares outstanding.

What happened to XTL Biopharmaceuticals Ltd. Sponsored ADR’s price movement after its last earnings report?

XTL Biopharmaceuticals Ltd. Sponsored ADR reported an EPS of -$0.169 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of XTL Biopharmaceuticals Ltd. Sponsored ADR?

Currently, no hedge funds are holding shares in XTLB

---

Company Description

XTL Biopharmaceuticals Ltd. Sponsored ADR

XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) is a biopharmaceutical company focused on the development, acquisition, and commercialization of pharmaceutical products for the treatment of unmet medical needs, primarily in the fields of autoimmune diseases and oncology. The company operates within the biotechnology and pharmaceutical sectors and is dedicated to advancing its pipeline of therapeutic candidates through clinical trials and strategic collaborations.

---

XTLB Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2015","6":"Oct<br/>2015","9":"Jan<br/>2016","12":"Mar<br/>2016","25":"Mar<br/>2017"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.74,2.5292307692307694,2.3184615384615386,2.1076923076923078,1.896923076923077,1.6861538461538463,1.4753846153846155,1.2646153846153847,1.0538461538461539,0.8430769230769231,0.6323076923076925,0.42153846153846164,0.21076923076923082,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.74,"date":1427846400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1430438400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1433116800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1435708800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1438387200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1441065600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1443657600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1446336000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1448928000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1451606400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1454284800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1456790400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.74,"date":1456790400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >